Siltuximab (CNTO-328) is a human-mouse chimeric monoclonal antibody that specifically targets interleukin-6 (IL-6). It is utilized in research for conditions like multicentric Castleman disease (MCD) and has been investigated in preclinical and clinical studies for its role in modulating cytokine storms, including in COVID-19 research.